Deworming drug, levamisole, is being evaluated by the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) following concerns about its links with leukoencephalopathy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results